[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has hypertrophic cardiomyopathy (HCM) with a significant left ventricular outflow tract (LVOT) gradient (80 mmHg) and recurrent syncope, indicating severe symptomatic obstructive HCM. He has failed optimal medical therapy with beta-blockers.\n\nLet's evaluate the options:\nA. Alcohol septal ablation: This is a percutaneous intervention used to reduce the LVOT gradient. It is an option for symptomatic obstructive HCM when medical therapy fails, but surgical myectomy is generally considered more effective and durable for severe obstruction, especially in younger patients.\nB. Surgical myectomy: This is the gold standard treatment for medically refractory symptomatic obstructive HCM. It involves surgically removing the thickened septal muscle to relieve the obstruction. Given the significant gradient (80 mmHg) and recurrent syncope, this is a highly appropriate option for a 58-year-old patient who is likely a surgical candidate.\nC. Implantation of a dual-chamber pacemaker: Pacing strategies have been explored for HCM, but they are not generally effective in significantly reducing high LVOT gradients or relieving symptoms in severe obstructive HCM, especially compared to myectomy or ablation.\nD. Addition of disopyramide: Disopyramide is an antiarrhythmic drug that can effectively reduce the LVOT gradient and symptoms in HCM. It is often used as a second-line medical therapy when beta-blockers are insufficient. However, the question states that the patient has \"failed optimal medical therapy with beta-blockers,\" implying that this line of treatment has been exhausted. While adding disopyramide is a possibility, the severity of symptoms (recurrent syncope) and the significant gradient might warrant a more definitive intervention sooner rather than later, especially if \"optimal\" implies maximally tolerated doses and consideration of other medical agents. However, if \"optimal medical therapy\" strictly implies only beta-blockers, then disopyramide would be the next medical step. Nevertheless, persistent significant obstruction and severe symptoms (syncope) often point towards invasive treatment.\nE. Cardiac resynchronization therapy (CRT): CRT is primarily indicated for heart failure with reduced ejection fraction and a wide QRS complex, not for managing LVOT obstruction in HCM.\n\nConsidering the severity of the obstruction (80 mmHg gradient) and the serious symptom of recurrent syncope, the patient is a strong candidate for definitive treatment to relieve the LVOT obstruction. Surgical myectomy offers the most complete and durable relief of obstruction and is generally preferred over alcohol septal ablation for significant, symptomatic obstructive HCM in suitable surgical candidates. While disopyramide is a valid medical option, the degree of obstruction and the recurrent syncope suggest that an invasive procedure might be the most appropriate next step for achieving significant symptom improvement and preventing adverse events. Between surgical myectomy and alcohol septal ablation, myectomy is considered superior for severe obstruction.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "B. Renal coloboma syndrome"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\n\nRationale:\nThe patient presents with an acute pulmonary embolism (PE). Her risk factors include recent long-haul flight, oral contraceptive use, a history of thrombophilia in the family, and elevated factor VIII levels. The PE is described as segmental, and there is no mention of hemodynamic instability or right heart strain, suggesting it is likely not a massive PE requiring thrombolysis.\n\nLet's evaluate the options for initial anticoagulant therapy:\n\nA. Low-molecular-weight heparin followed by warfarin: This is a traditional and effective treatment regimen for PE. LMWH provides rapid anticoagulation, and warfarin provides longer-term anticoagulation after an initial overlap period.\n\nB. Direct oral anticoagulant such as rivaroxaban: DOACs like rivaroxaban are now widely recommended and used as first-line therapy for acute VTE, including PE, especially in patients with provoked VTE and without contraindications. They offer rapid onset of action, oral administration, and typically do not require initial parenteral bridging or frequent monitoring (like INR for warfarin). For hemodynamically stable patients with acute PE, DOACs are generally preferred due to their convenience and proven efficacy and safety.\n\nC. Unfractionated heparin with thrombolysis: Thrombolysis is indicated for patients with massive PE (hemodynamic instability) or submassive PE with signs of clinical deterioration or right ventricular dysfunction. A segmental PE without mentioned instability does not warrant thrombolysis.\n\nD. Fondaparinux monotherapy: Fondaparinux is a parenteral anticoagulant that can be used for PE treatment. It is effective but may require transition to an oral agent for long-term management, and DOACs are often preferred for their oral administration and broader evidence base for long-term use in many scenarios.\n\nE. Aspirin and clopidogrel combination: These are antiplatelet agents used for arterial thrombosis, not for venous thromboembolism like PE. They are not effective for treating or preventing PE.\n\nConsidering current guidelines for VTE management, DOACs like rivaroxaban are often the most appropriate initial choice for patients with acute PE who are hemodynamically stable and do not have contraindications. The patient's risk factors (travel, OCPs, family history) suggest VTE but do not preclude the use of a DOAC. Thus, rivaroxaban is a suitable and often preferred initial therapy.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. These symptoms suggest a systemic inflammatory condition affecting the joints and skin. Laboratory tests show positive anti-citrullinated protein antibodies (ACPA), which is a highly specific marker for Rheumatoid Arthritis (RA). Elevated inflammatory markers are consistent with inflammation. Methotrexate therapy, a first-line treatment for RA, is initiated but the disease progresses, suggesting either refractory RA or an alternative diagnosis.\n\nThe crucial piece of information revealed by genetic testing is a mutation in the NLRP3 gene. Mutations in the NLRP3 gene are the underlying cause of a group of autoinflammatory diseases known as Cryopyrin-Associated Periodic Syndromes (CAPS). CAPS are characterized by recurrent episodes of fever, rash (often urticarial or urticarial-like), arthralgias, and arthritis, along with systemic inflammation. Symmetric polyarthritis and skin rash can be features of CAPS.\n\nLet's analyze the options:\nA. Rheumatoid arthritis: While the symptoms (symmetric polyarthritis, morning stiffness) and positive ACPA strongly suggest RA, the presence of an NLRP3 gene mutation is not typical for RA. The failure of methotrexate might occur in RA but doesn't explain the genetic finding.\n\nB. Cryopyrin-associated periodic syndrome (CAPS): This is directly linked to mutations in the NLRP3 gene. The symptoms of polyarthritis and rash are compatible with some presentations of CAPS. While positive ACPA is not a diagnostic criterion for CAPS, it's possible to have co-existing conditions or less typical presentations. Given the definitive genetic finding, CAPS becomes the most likely diagnosis that explains the entire clinical picture, especially the genetic basis.\n\nC. Adult-onset Still's disease (AOSD): AOSD typically presents with fever, rash (often salmon-colored), and arthritis. However, ACPA are usually negative in AOSD, and NLRP3 mutations are not associated with it.\n\nD. Behçet's disease: This is a systemic vasculitis with characteristic oral/genital ulcers, skin lesions, and uveitis. While arthritis can occur, symmetric polyarthritis and morning stiffness are not the primary joint manifestations, ACPA are negative, and NLRP3 mutations are unrelated.\n\nE. Systemic lupus erythematosus (SLE): SLE can present with arthritis, rash, and systemic inflammation. However, ACPA are typically negative in SLE (ANA is usually positive), and NLRP3 mutations are not directly linked to SLE.\n\nThe presence of a specific pathogenic gene mutation (NLRP3) that directly causes a defined group of diseases (CAPS) is the most precise and etiologically significant finding. The described symptoms, while overlapping with RA, are also compatible with CAPS. Therefore, the genetic finding strongly points towards CAPS as the most likely diagnosis.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has type 1 diabetes mellitus (T1DM), which is characterized by autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency. This means endogenous insulin and C-peptide production are very low or undetectable. The finding of low C-peptide confirms this.\n\nThe patient is experiencing recurrent hypoglycemia despite insulin dose adjustments, particularly nocturnal hypoglycemia. This indicates an excessive effect of insulin.\n\nThe laboratory evaluation reveals elevated proinsulin levels and a low C-peptide.\n*   Low C-peptide: Confirms the lack of endogenous insulin secretion, consistent with T1DM. This automatically rules out endogenous insulin-producing tumors like insulinoma, which typically present with high C-peptide levels.\n*   Elevated proinsulin: In the absence of endogenous insulin production (low C-peptide), elevated proinsulin strongly suggests that the source is exogenous. Standard exogenous insulin preparations are primarily insulin, but can contain trace amounts of proinsulin. If a patient is intentionally administering excessive doses of exogenous insulin, or administering an impure source, this could lead to elevated proinsulin levels. \"Factitious hypoglycemia\" refers to self-induced hypoglycemia, often by administering excessive amounts of insulin.\n\nLet's evaluate the options:\nA.  Insulinoma: Ruled out by low C-peptide.\nB.  Factitious hypoglycemia from exogenous insulin: This is highly consistent. The patient has T1DM (low C-peptide) and is likely administering excessive exogenous insulin, leading to hypoglycemia. The elevated proinsulin could be due to trace amounts in the injected insulin preparation.\nC.  Adrenal insufficiency: Can cause hypoglycemia, but does not directly explain elevated proinsulin with low C-peptide in a T1DM patient.\nD.  Autoimmune hypoglycemia: While possible in a patient with T1DM (as they are prone to autoimmune diseases), the primary mechanism is the presence of antibodies against insulin, which can prolong the action of exogenous insulin. Elevated proinsulin is not a hallmark feature of this condition, although altered insulin metabolism can occur. However, direct administration of exogenous insulin that is not purely insulin is a more direct explanation for elevated proinsulin.\nE.  Nesidioblastosis: This is a condition of neonatal hyperinsulinism due to islet cell hyperplasia, characterized by high insulin and high C-peptide. It is not relevant to an adult with T1DM.\n\nConsidering all findings, factitious hypoglycemia from exogenous insulin is the most likely underlying mechanism that explains recurrent hypoglycemia, low C-peptide (due to T1DM), and elevated proinsulin (from exogenous administration).\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has recurrent sustained ventricular tachycardia (VT) despite amiodarone therapy. Electrophysiology study has identified a reentrant circuit in the infarct border zone, confirming the mechanism and location of the VT. In patients with structural heart disease and recurrent VT that is refractory to antiarrhythmic drugs, catheter ablation targeting the reentrant circuit is a highly effective intervention to prevent future episodes and reduce the burden of VT.\n\nOption A, Catheter ablation, directly addresses the identified reentrant circuit. This is a standard treatment for drug-refractory VT in patients with structural heart disease.\n\nOption B, Implantable cardioverter-defibrillator (ICD) upgrade to biventricular (CRT-ICD), is important for patients with reduced ejection fraction (EF) to prevent sudden cardiac death due to VT/VF. However, an ICD primarily terminates VT episodes rather than eliminating the underlying circuit that causes recurrence. While CRT may improve cardiac function, it is not the primary treatment for recurrent VT after antiarrhythmic drug failure. If the patient does not already have an ICD, it would be indicated, but ablation addresses the *recurrence* more directly. If they do have an ICD, and VT is recurrent, ablation is often considered to reduce VT burden and ICD shocks.\n\nOption C, Addition of mexiletine, is another antiarrhythmic drug. Given that amiodarone, a potent antiarrhythmic, has failed, and a specific circuit has been identified, escalating drug therapy may be less effective and carry more side effects than a targeted ablation procedure.\n\nOptions D and E, Stellate ganglionectomy and Cardiac sympathetic denervation, are interventions targeting the sympathetic nervous system. These are typically considered for specific types of refractory VT (e.g., those triggered by sympathetic activity) or when other, more standard treatments like ablation have failed. They are generally not the first-line next step for a well-defined reentrant circuit in the infarct border zone.\n\nConsidering the identified reentrant circuit and failure of amiodarone, catheter ablation is the most appropriate next intervention to eliminate the VT substrate.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with short stature, failure to thrive, delayed bone age, low IGF-1, and normal GH stimulation. Genetic testing reveals a mutation in the IGF1R gene. This constellation of findings indicates GH insensitivity or primary IGF-1 deficiency due to a defect in the IGF-1 receptor.\n\nLet's analyze the options:\nA. Recombinant growth hormone therapy: GH replacement is typically indicated for GH deficiency. This patient has normal GH levels after stimulation, suggesting the pituitary is functioning correctly. GH acts by stimulating the liver to produce IGF-1. If the IGF-1 receptor is defective, even if GH stimulates IGF-1 production, IGF-1 will not be able to signal effectively through its receptor. Thus, GH therapy is unlikely to be effective.\n\nB. IGF-1 replacement therapy: Since the patient has a mutation in the IGF1R gene, the cells are unable to respond properly to IGF-1. However, exogenous recombinant human IGF-1 (rhIGF-1) can bypass the defective receptor pathway by directly stimulating downstream intracellular signaling pathways. rhIGF-1 is the standard treatment for children with primary IGF-1 deficiency, which this condition represents due to the receptor defect.\n\nC. Nutritional supplementation: While failure to thrive may involve nutritional issues, the presence of a specific genetic defect in the IGF1R gene points to a primary underlying endocrine or genetic cause. Nutritional supplementation alone might not correct the growth deficit caused by the genetic defect.\n\nD. Thyroid hormone replacement: Hypothyroidism can cause short stature and delayed bone age. However, the specific findings of normal GH stimulation and low IGF-1, along with the IGF1R mutation, do not directly suggest hypothyroidism as the primary problem. Assessment of thyroid function should be part of a complete evaluation for short stature, but it's not the most appropriate *management strategy* given the specific genetic diagnosis.\n\nE. Corticosteroid therapy: Excess corticosteroids cause growth suppression. There is no indication for corticosteroid therapy in this case.\n\nGiven the genetic mutation in the IGF1R gene, leading to impaired IGF-1 signaling despite adequate GH production, direct administration of IGF-1 is the most appropriate management strategy to promote growth.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with severe acute pancreatitis complicated by necrosis, hypotension, and acute kidney injury, with serum triglycerides of 1200 mg/dL. Severe hypertriglyceridemia, defined as levels >1000 mg/dL, is a known cause of acute pancreatitis and requires prompt management to reduce triglyceride levels and mitigate further organ damage.\n\nLet's evaluate the options for initial management:\nA. Plasmapheresis: This procedure can rapidly remove triglycerides from the blood. It is usually considered in cases of very severe hypertriglyceridemic pancreatitis, particularly when triglyceride levels are extremely high (e.g., >2000 mg/dL) or when there is significant organ dysfunction or failure that is refractory to other treatments.\n\nB. Insulin infusion: Intravenous insulin infusion is a well-established and highly effective method for rapidly lowering triglyceride levels, especially in the context of acute pancreatitis. Insulin activates lipoprotein lipase, which is essential for the clearance of triglyceride-rich lipoproteins. It is often considered the first-line therapy for severe hypertriglyceridemic pancreatitis with triglyceride levels >1000 mg/dL, especially in the presence of organ dysfunction.\n\nC. Fibrates: Fibrates are oral medications that lower triglycerides but have a slow onset of action and are not suitable for acute management of severe hypertriglyceridemia causing pancreatitis.\n\nD. Niacin: Niacin also lowers triglycerides but is not effective for acute management and has a slow onset of action.\n\nE. Statins: Statins are primarily used to lower LDL cholesterol and have a limited effect on severe hypertriglyceridemia. They are not the primary treatment for acute hypertriglyceridemic pancreatitis.\n\nConsidering the patient's triglyceride level of 1200 mg/dL and the presence of severe pancreatitis with organ dysfunction (hypotension, AKI), rapid triglyceride reduction is critical. While plasmapheresis is an option for severe cases, current guidelines and clinical practice widely recommend intravenous insulin infusion as the most appropriate *initial* management for hypertriglyceridemia >1000 mg/dL in acute pancreatitis. It is readily available, effective, and generally well-tolerated. Plasmapheresis is typically reserved for cases where insulin infusion is insufficient or for extremely elevated triglyceride levels.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with constitutional symptoms (fever, weight loss, lymphadenopathy) and is on infliximab, a TNF-alpha inhibitor, for rheumatoid arthritis. Infliximab can increase the risk of infections, including tuberculosis, and can also induce or unmask sarcoidosis. The biopsy shows non-caseating granulomas, which are characteristic of sarcoidosis. Elevated serum angiotensin-converting enzyme (ACE) levels further support the diagnosis of sarcoidosis, as ACE is primarily produced by macrophages in granulomas.\n\nLet's evaluate the options:\nA. Tuberculosis reactivation: While infliximab increases TB risk, TB typically causes caseating granulomas, not non-caseating granulomas, and elevated ACE is not a feature of TB.\nB. Infliximab-induced sarcoidosis: TNF-alpha inhibitors are known to cause sarcoidosis. The presence of non-caseating granulomas and elevated ACE is classic for sarcoidosis, and the temporal association with infliximab treatment makes this diagnosis highly likely.\nC. Lymphoma: Lymphoma can cause systemic symptoms and lymphadenopathy, but non-caseating granulomas and elevated ACE are not typical findings.\nD. Fungal infection: Some fungal infections can cause granulomas, but non-caseating granulomas and elevated ACE are not their most common presentation, and sarcoidosis is a stronger fit for the given findings.\nE. Amyloidosis: Amyloidosis is a deposition disease and does not involve granuloma formation or elevated ACE.\n\nThe combination of non-caseating granulomas and elevated ACE in a patient on infliximab strongly suggests sarcoidosis, which can be unmasked or induced by TNF-alpha inhibitors.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has acromegaly with persistently elevated IGF-1 levels after transsphenoidal surgery and refusal of further surgery. This indicates the need for pharmacologic therapy. The standard treatment algorithm for acromegaly involves surgery as the first-line treatment, followed by medical therapy if surgery is unsuccessful or not feasible.\n\nThe first-line pharmacologic treatment for acromegaly typically involves somatostatin analogs (SSAs) such as octreotide or lanreotide. These medications work by inhibiting the secretion of growth hormone (GH) from the pituitary tumor.\n\nLet's consider the other options:\nB. Pegvisomant is a GH receptor antagonist. It is effective in lowering IGF-1 levels by blocking GH action, but it is usually considered a second-line therapy when SSAs are insufficient or not tolerated.\nD. Pasireotide is also a somatostatin analog, but it is a multi-receptor targeting agent. It is often used when first-generation somatostatin analogs like octreotide or lanreotide are insufficient.\nA and E. Cabergoline and bromocriptine are dopamine agonists. While they can lower GH and IGF-1 levels in some patients with acromegaly, they are generally less effective than SSAs or pegvisomant and are often reserved for patients with co-secreting GH and prolactin tumors or as adjunctive therapy.\n\nGiven that the patient requires pharmacologic intervention after failed surgery, the most appropriate initial step is to initiate treatment with a somatostatin analog. Octreotide is a representative example of this class of drugs and is the standard of care in this situation.\n\nThe final answer is $\\boxed{C}$."}]